Home > Boards > US Listed > Biotechs >

Regen BioPharma Inc. (RGBP)

RGBP RSS Feed
Add RGBP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, trazbull, PepsiMan, BigBadWolf, Papa Bear, #1_USA_DEPLORABLE
Search This Board: 
Last Post: 5/23/2019 10:53:35 PM - Followers: 366 - Board type: Free - Posts Today: 0

REMEMBER Koos has other FAILED, price-wise, OTC stinky pinky stocks! Do a search and you will find ample info about him and his "doings".
Always research for yourself BEFORE you buy in the OTC stinky pinky area!!!!



Picture



REGEN BIOPHARMA, INC.
4700 Spring Street, Suite 304
La Mesa, CA 91942
U.S.A.


Telephone: (619) 702-1404
Fax: (619) 330-2328
 

 






Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).






 

Product Pipeline | Regen BioPharma, Inc.



 

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD
 

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



     

dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 


     

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia



     

Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia





     
PictureImage result for news





Image result for cbd



 

Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease

 

SAN DIEGO, January 8, 2019 /PRNewswire/ --   https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Examines-Combining-Cannabidiol-CBD-With-Its-Lead-NR2F6-Agonist-To-Treat-for-Inflammatory-Bowel-Disea?id=214869

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.

"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."

 

All other Regen BioPharma News Articles:  https://www.otcmarkets.com/stock/RGBP/news





RGBP
RGBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#35614  Sticky Note yea let Koos open his mouth in any BigBadWolf 05/10/19 02:43:46 PM
#33083  Sticky Note Regen BioPharma, Inc. Reports Activation of Immune Cells jedijazz 09/21/18 09:37:04 AM
#27909  Sticky Note ELI LILLY HAS RGBP SCREENING COMPOUNDS FOR THEM!!!!!!!!!!! gotinearly 06/30/16 09:23:49 AM
#35636   Unlike the 237th time that’s been posted on SidVicious 05/23/19 10:53:35 PM
#35635   RGBP watching for reversal soon azco_com 05/23/19 04:26:58 PM
#35634   It is surprising we haven't heard a peep SidVicious 05/22/19 09:16:24 AM
#35633   RGBPP $467 in trading volume today? Ten trades. SanDiegoAlan 05/21/19 03:42:56 PM
#35631   look at RGBPP---maybe RGBP will be next !! BONGWHOLE 05/21/19 02:04:51 PM
#35630   Anyone have the current S/S? Arnold25764 05/20/19 01:13:05 AM
#35629  Restored TRADE OF THE YEAR ALRIGHT!!!!!!!!! #1_USA_DEPLORABLE 05/16/19 10:09:58 AM
#35628  Restored $RGBP is the trade of the year? SidVicious 05/16/19 08:21:01 AM
#35627  Restored Then slap a reverse split on it and #1_USA_DEPLORABLE 05/15/19 07:10:58 AM
#35626   BMSN low. That’s how low SidVicious 05/14/19 11:58:12 PM
#35625   Holy F how low is this going to CJ Investor 05/14/19 07:00:00 PM
#35624   Denny's for the Shareholder meeting? What does Koos sizzleweed 05/14/19 12:49:38 AM
#35623   who gives a rats ask...Koon's did not notice BigBadWolf 05/13/19 09:37:44 AM
#35622   Leaked by the fraudsters that issued an unauthorized gotinearly 05/13/19 09:25:46 AM
#35620   It's held at the Denny's in La Mesa,CA. SanDiegoAlan 05/11/19 04:27:18 AM
#35619   Never happen or happened! lab40 05/10/19 06:30:06 PM
#35618   When and where is the annual (sharholders) meeting? Halp 05/10/19 03:17:07 PM
#35617   Koos blows a lot of smoke & always has! BigBadWolf 05/10/19 03:06:39 PM
#35616   LOL, it was issued on day one. gotinearly 05/10/19 03:04:30 PM
#35615   RGBP Merger Post Was NOT Approved By David the reaper 05/10/19 02:44:42 PM
#35614   yea let Koos open his mouth in any BigBadWolf 05/10/19 02:43:46 PM
#35613   RGBP Has Put Out Two 8K's to Address the reaper 05/10/19 02:38:58 PM
#35612   Yes indeed, and nice pricing right here IMO sharky 05/10/19 12:11:53 PM
#35611   company been pretty good about setting the record straight. Rainer 05/10/19 11:49:22 AM
#35610   Company did not release the fake news, might sharky 05/10/19 11:36:25 AM
#35609   Ok. Epson 05/10/19 09:50:19 AM
#35608   No it's the CBD filled doggie treats which lab40 05/10/19 01:30:09 AM
#35607   You are right. PR tomorrow after the close SidVicious 05/09/19 10:33:38 PM
#35606   I'm definitely holding---not going anywhere....I have a gut BONGWHOLE 05/09/19 09:23:16 PM
#35605   Better than Konman Koos who was late to SidVicious 05/09/19 06:10:16 PM
#35604   Bailed yesterday. Sold it all not thinking audioguy 05/09/19 02:43:35 PM
#35603   whose holding? Epson 05/09/19 02:24:52 PM
#35602  Restored how's the chicken w/ Fake & Bake crust BigBadWolf 05/09/19 11:30:23 AM
#35601   TRACK EM DOWN AND HAVE THE SEC/EFF BEE #1_USA_DEPLORABLE 05/09/19 09:52:58 AM
#35600   This is holding well considering, I got out pb_trading 05/09/19 09:44:30 AM
#35599   Fake & Bake Koos chicken http://archive.fast-edgar.com//20190508/AEZPG22C2222D2 BigBadWolf 05/09/19 09:28:15 AM
#35598   News hit equity feed yesterday. Rainer 05/09/19 08:09:43 AM
#35597   Hmmmmmm, so we SEE who STARTED this #1_USA_DEPLORABLE 05/09/19 08:08:00 AM
#35596   $RGBP Regen BioPharma, Inc. Responds to Fake News StockHighAlert- 05/09/19 07:38:36 AM
#35595   Scammers gonna scam. You can bet the noteholders, SanDiegoAlan 05/08/19 11:00:22 PM
#35593   LOL! A Fake company called REGEN got trolled SidVicious 05/08/19 08:53:06 PM
#35592   Yup, RGBP getting a lot attention we see slickinvest 05/08/19 08:04:49 PM
#35590   It was running before fake news, oversold, good pb_trading 05/08/19 07:44:54 PM
#35589   GOT MY BID @ .0003 ;-) @__FREEMONEY 05/08/19 06:31:12 PM
#35588   RGBPstill a buyer at this level $$ slickinvest 05/08/19 06:30:27 PM
#35587   Welcome to Koosland! lab40 05/08/19 06:01:50 PM
#35586   Takes a real ass bag to put out cheata425 05/08/19 05:53:04 PM
#35584   Sucks it was fake news, all the signs pb_trading 05/08/19 05:40:56 PM
#35583   HAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHA RGBP. 100 million and it went DOWN!!!! #1_USA_DEPLORABLE 05/08/19 05:23:49 PM
#35582   These guys should be put in jail jet101 05/08/19 05:14:20 PM
PostSubject